Rapid Response in a Patient with Relapsed/Refractory Multiple Myeloma Treated with BRAF/MEK Inhibitors

Figure 1

Response to treatment. (a) M protein levels after initiation of treatment with vemurafenib and cobimetinib at 0, 5, 9, 13, 16, 25, and 37 weeks. (b) Changes in kappa/lambda ratio at 0, 5, 9, 13, 16, 25, and 37 weeks. The beige box shows the normal range of the kappa/lambda ratio.

(a)

(b)